<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586231</url>
  </required_header>
  <id_info>
    <org_study_id>6482-011</org_study_id>
    <secondary_id>2020-002075-35</secondary_id>
    <secondary_id>MK-6482-011</secondary_id>
    <secondary_id>jRCT2031210311</secondary_id>
    <nct_id>NCT04586231</nct_id>
  </id_info>
  <brief_title>A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)</brief_title>
  <official_title>An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy and safety of belzutifan + lenvatinib versus&#xD;
      cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell&#xD;
      component after prior therapy.&#xD;
&#xD;
      The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms&#xD;
      of progression-free survival or overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 34 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 44 months</time_frame>
    <description>OS is defined as time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to approximately 44 months</time_frame>
    <description>For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 44 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 44 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">708</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Belzutifan + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belzutifan 120 mg and lenvatinib 20 mg orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cabozantinib 60 mg orally once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belzutifan</intervention_name>
    <description>Immediate-release 40 mg tablet</description>
    <arm_group_label>Belzutifan + Lenvatinib</arm_group_label>
    <other_name>PT2977</other_name>
    <other_name>MK-6482</other_name>
    <other_name>WELIREG™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Capsule available in 4 mg and 10 mg dosages</description>
    <arm_group_label>Belzutifan + Lenvatinib</arm_group_label>
    <other_name>Lenvima</other_name>
    <other_name>E7080</other_name>
    <other_name>MK-7902</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Tablet available in 20 mg, 40 mg and 60 mg dosages</description>
    <arm_group_label>Cabozantinib</arm_group_label>
    <other_name>Cabometyx</other_name>
    <other_name>Cometriq</other_name>
    <other_name>XL184</other_name>
    <other_name>BMS-907351</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC).&#xD;
&#xD;
          -  Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1)&#xD;
             therapy as either first or second-line treatment for locally advanced/metastatic RCC&#xD;
             or as adjuvant treatment with progression on or within 6 months of last dose.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1 criteria as assessed by local study investigator.&#xD;
&#xD;
          -  Karnofsky performance status (KPS) score of at least 70% assessed within 10 days&#xD;
             before randomization.&#xD;
&#xD;
          -  Received no more than 2 prior systemic regimens.&#xD;
&#xD;
          -  Received only 1 prior antiPD-1/L1 therapy for adjuvant or locally advanced/metastatic&#xD;
             RCC.&#xD;
&#xD;
          -  A male participant is eligible to participate if he is abstinent from heterosexual&#xD;
             intercourse or agrees to use contraception during the intervention period and for at&#xD;
             least 7 days after the last dose of belzutifan or lenvatinib in the&#xD;
             belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of&#xD;
             cabozantinib.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least 1 of the following conditions applies: Not a woman of&#xD;
             childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive&#xD;
             guidance during the intervention period and for at least 30 days after the last dose&#xD;
             of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last&#xD;
             dose of study intervention in the cabozantinib arm.&#xD;
&#xD;
          -  Adequately controlled blood pressure.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A pulse oximeter reading &lt;92% at rest, requires intermittent supplemental oxygen, or&#xD;
             requires chronic supplemental oxygen.&#xD;
&#xD;
          -  Known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years except for basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in&#xD;
             situ) that have undergone potentially curative therapy.&#xD;
&#xD;
          -  Known central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Clinically significant cardiac disease within 6 months of first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  Prolongation of QTc interval to &gt;480 ms.&#xD;
&#xD;
          -  Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not&#xD;
             clinically stable.&#xD;
&#xD;
          -  Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.&#xD;
&#xD;
          -  Moderate to severe hepatic impairment.&#xD;
&#xD;
          -  History of significant bleeding within 3 months before randomization.&#xD;
&#xD;
          -  History of solid organ transplantation.&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorder that would interfere with cooperation&#xD;
             with the requirements of the study.&#xD;
&#xD;
          -  Unable to swallow orally administered medication or has a gastrointestinal disorder&#xD;
             affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption).&#xD;
&#xD;
          -  Known hypersensitivity or allergy to the active pharmaceutical ingredients or any&#xD;
             component of the study intervention formulations.&#xD;
&#xD;
          -  Received colony-stimulating factors [eg, granulocyte colony-stimulating factor&#xD;
             (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant&#xD;
             erythropoietin (EPO)] within 28 days before randomization.&#xD;
&#xD;
          -  Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α&#xD;
             inhibitor.&#xD;
&#xD;
          -  Prior treatment with lenvatinib.&#xD;
&#xD;
          -  Prior treatment with cabozantinib.&#xD;
&#xD;
          -  Currently participating in a study of an investigational agent or using an&#xD;
             investigational device.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  History of hepatitis B or known active hepatitis C infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ironwood Cancer &amp; Research Centers ( Site 0077)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-398-7674</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center ( Site 0027)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-423-3713</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Santa Monica ( Site 0048)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-633-8400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center ( Site 0083)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-315-6125</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center ( Site 0006)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-687-1116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando-AdventHealth Medical Group Hematology &amp; Oncology at Orlando ( Site 0003)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-303-2024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health, Inc. ( Site 0035)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>321-841-3812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center, LLC ( Site 0057)</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-353-2990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital ( Site 0012)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center ( Site 0040)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-942-3732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, PC ( Site 0008)</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>309-243-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkview Cancer Institute ( Site 0088)</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>260-266-7745</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St. Matthews ( Site 0065)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-899-3366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center ( Site 0090)</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>781-744-2998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Centers of Western Michigan ( Site 0018)</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>269-993-6056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center - HealthPartners/Park Nicollet-Oncology Research - Park Nicollet ( Site 0005)</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>952-993-6705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Partners of Nebraska ( Site 0086)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-420-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey ( Site 0078)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-235-2465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health- Monter Cancer Center ( Site 0013)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-734-8916</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center ( Site 0055)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-888-4722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute ( Site 0004)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>980-442-9715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>610-402-1184</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center ( Site 0015)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-645-8787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center ( Site 0001)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>802-656-4909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care - Roanoke ( Site 0043)</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-381-5291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Confluence Health | Wenatchee Valley Hospital &amp; Clinics ( Site 0061)</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-664-4868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital ( Site 4004)</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6188282 0833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Health Frankston Hospital ( Site 4001)</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61397847175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre ( Site 4010)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61385595000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+43 149 150 2145</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)</name>
      <address>
        <city>Wien</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>431211212100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien ( Site 1021)</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+43 1 40400 44290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet ( Site 1103)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3225417320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi ( Site 1104)</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3271104750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 1100)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 1101)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>003216346900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Liege ( Site 1102)</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>003243667801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liga Norte Riograndense Contra o Cancer ( Site 0313)</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59151600</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+558440095595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Gaucho Integrado de Oncologia ( Site 0304)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>55 51 3307.2943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0311)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5511 3505 6675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala ( Site 1801)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331163082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HYKS ( Site 1800)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358504279697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TYKS ( Site 1802)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35823130729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne ( Site 1217)</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33492031538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud ( Site 1215)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155829</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Francois Chenieux ( Site 1210)</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33555454800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33(0)240679900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon ( Site 1213)</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156017110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg Nord ( Site 1300)</name>
      <address>
        <city>Nuremberg</city>
        <state>Bayern</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 911 398 3085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Aachen AOER ( Site 1317)</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49 241 80 36596</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha Maria Halle-Doelau ( Site 1314)</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493455591449</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH ( Site 1315)</name>
      <address>
        <city>Erfurt</city>
        <state>Thuringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00493617812201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin ( Site 1321)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0049 30 450 615092</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch ( Site 1311)</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0049 30 9401 14888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujita Health University ( Site 5003)</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-562-93-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 5000)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-4-7133-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital ( Site 5008)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-11-611-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital ( Site 5007)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-787-2800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 5002)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-744-22-3051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine University Hospital ( Site 5004)</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-53-435-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Medical Hospital ( Site 5009)</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital ( Site 5001)</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3588-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital ( Site 5006)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3822-2131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio university hospital ( Site 5011)</name>
      <address>
        <city>Tokyo</city>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3353-1211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden ( Site 1905)</name>
      <address>
        <city>Leeuwarden</city>
        <state>Fryslan</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31582866666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)</name>
      <address>
        <city>Sittard-Geleen</city>
        <state>Limburg</state>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31582866010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital Location Molengracht ( Site 1912)</name>
      <address>
        <city>Breda</city>
        <state>Noord-Brabant</state>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31765955000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31205122569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC ( Site 1913)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107041754</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht ( Site 1910)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31887555555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Oncology Dispensary ( Site 2616)</name>
      <address>
        <city>Ivanovo</city>
        <state>Ivanovskaya Oblast</state>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8 493 256 9489</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)</name>
      <address>
        <city>Krasnogorsk</city>
        <state>Moskovskaya Oblast</state>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>84957305726</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical-Oncology department ( Site 2609)</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaya Oblast</state>
        <zip>121205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74958001000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI United Hospital with Polyclinic ( Site 2613)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119285</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74953333000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955360222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Uronephrological Center ( Site 2615)</name>
      <address>
        <city>Volzhsky</city>
        <state>Volgogradskaya Oblast</state>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78443274477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74852208100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruna ( Site 1502)</name>
      <address>
        <city>A Coruna</city>
        <state>La Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial ( Site 1500)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau ( Site 1501)</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34935537453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 1505)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 1504)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000 x3133</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio ( Site 1503)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955013068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG ( Site 1602)</name>
      <address>
        <city>Geneva</city>
        <state>Geneve</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41795532353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden ( Site 1600)</name>
      <address>
        <city>Chur</city>
        <state>Grisons</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41812566646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41918118463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 1601)</name>
      <address>
        <city>Zuerich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492118108776</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

